Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 3, 2012, Pages 613-622

  Derwall, Matthias ^a,d   Malhotra, Rajeev ^b   Lai, Carol S ^b   Beppu, Yuko ^a   Aikawa, Elena ^c   Seehra, Jasbir S ^e   Zapol, Warren M ^a   Bloch, Kenneth D ^a,b   Yu, Paul B ^b,f  

^a Division of Pulmonary Critical Care and Sleep Medicine   (United States)

^b Cardiovascular Research Center   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e Acceleron Pharma Inc   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

atherosclerosis; calcification; lipids; reactive oxygen species; signal transduction

Indexed keywords

APOLIPOPROTEIN B100; BONE MORPHOGENETIC PROTEIN; LDN 193189; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG POTENCY; DRUG TOLERABILITY; ENDOTHELIUM CELL; FATTY LIVER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEINS; CARDIOVASCULAR AGENTS; CHOLESTEROL, LDL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FATTY LIVER; FEMALE; HEP G2 CELLS; HUMANS; LIPOPROTEINS, LDL; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRAZOLES; PYRIMIDINES; REACTIVE OXYGEN SPECIES; RECEPTORS, LDL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR CALCIFICATION;

EID: 84857650449     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.242594     Document Type: Article

References (53)

1. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22:233-241. (Pubitemid 40136452)
2. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1:169-178.
3. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: Transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005;16:251-263. (Pubitemid 40910315)
4. Xia Y, Yu PB, Sidis Y, Beppu H, Bloch KD, Schneyer AL, Lin HY. Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem. 2007;282:18129-18140. (Pubitemid 47100254)
5. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem. 1999;274: 584-594.
6. Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809. (Pubitemid 23127387)
7. Neven E, Dauwe S, De Broe ME, D'Haese PC, Persy V. Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int. 2007;72:574-581. (Pubitemid 47312790)
8. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998-2003. (Pubitemid 34219753)
9. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol. 2010;7:528-536.
10. Boström K, Demer LL. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr. 2000;10:151-158.
11. Boström KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res. 2011;108:446-457.
12. Nakagawa Y, Ikeda K, Akakabe Y, Koide M, Uraoka M, Yutaka KT, Kurimoto-Nakano R, Takahashi T, Matoba S, Yamada H, Okigaki M, Matsubara H. Paracrine osteogenic signals via bone morphogenetic protein-2 accelerate the atherosclerotic intimal calcification in vivo. Arterioscler Thromb Vasc Biol. 2010;30:1908-1915.
13. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol. 2004;165:625-630. (Pubitemid 38765764)
14. Boström K, Tsao D, Shen S, Wang Y, Demer LL. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem. 2001;276:14044-14052.
15. Zebboudj AF, Imura M, Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002;277: 4388-4394. (Pubitemid 34968705)
16. Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, Boström KI. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010;107:485-494.
17. Hsu JJ, Tintut Y, Demer LL. Murine models of atherosclerotic calcification. Curr Drug Targets. 2008;9:224-228. (Pubitemid 351843604)
18. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93:1885-1893. (Pubitemid 24143065)
19. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008;18:4388-4392.
20. Steinbicker AU, Sachidanandan C, Vonner AJ, Yusuf RZ, Deng DY, Lai CS, Rauwerdink KM, Winn JC, Saez B, Cook CM, Szekely BA, Roy CN, Seehra JS, Cuny GD, Scadden DT, Peterson RT, Bloch KD, Yu PB. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011;117:4915-4923.
21. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116:2841-2850. (Pubitemid 350301146)
22. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007; 115:377-386. (Pubitemid 46148512)
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159. (Pubitemid 17064313)
24. Ichinose F, Buys ES, Neilan TG, Furutani EM, Morgan JG, Jassal DS, Graveline AR, Searles RJ, Lim CC, Kaneki M, Picard MH, Scherrer-Crosbie M, Janssens S, Liao R, Bloch KD. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shock. Circ Res. 2007;100:130-139. (Pubitemid 46066781)
25. Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, Boyd NL, Platt MO, Lassegue B, Griendling KK, Jo H. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95:773-779. (Pubitemid 39390579)
26. Abid MR, Spokes KC, Shih SC, Aird WC. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem. 2007;282:35373-35385. (Pubitemid 350232487)
27. Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal. 2010;13: 39-75.
28. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001;31:509-519. (Pubitemid 32728438)
29. Shao JS, Aly ZA, Lai CF, Cheng SL, Cai J, Huang E, Behrmann A, Towler DA. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann N Y Acad Sci. 2007;1117:40-50. (Pubitemid 350191291)
30. Su X, Ao L, Shi Y, Johnson TR, Fullerton DA, Meng X. Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via toll-like receptors 2 and 4. J Biol Chem. 2011;286:12213-12220.
31. Zhang M, Zhou SH, Li XP, Shen XQ, Fang ZF, Liu QM, Qiu SF, Zhao SP. Atorvastatin downregulates BMP-2 expression induced by oxidized low-density lipoprotein in human umbilical vein endothelial cells. Circ J. 2008;72:807-812. (Pubitemid 351716687)
32. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49:1537-1544.
33. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009;106: 15430-15435.
34. Rodriguez-Sanabria F, Rull A, Aragones G, Beltran-Debon R, Alonso-Villaverde C, Camps J, Joven J. Differential response of two models of genetically modified mice fed with high fat and cholesterol diets: rela-tionship to the study of non-alcoholic steatohepatitis. Mol Cell Biochem. 2010;343:59-66.
35. Hartvigsen K, Binder CJ, Hansen LF, Rafia A, Juliano J, Horkko S, Steinberg D, Palinski W, Witztum JL, Li AC. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007;27:878-885. (Pubitemid 46606720)
36. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lutjohann D, Kerksiek A, van Kruchten R, Maeda N, Staels B, van Bilsen M, Shiri-Sverdlov R, Hofker MH. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology. 2008;48:474-486.
37. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and nonalcoholic fatty liver disease. Killing two birds with one stone? Ann Med. 2011;43:167-171.
38. Maroni L, Guasti L, Castiglioni L, Marino F, Contini S, Macchi V, De Leo A, Gaudio G, Tozzi M, Grandi AM, Cosentino M, Venco A. Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease. Am J Med Sci. 2011;342:383-387.
39. Yao Y, Shao ES, Jumabay M, Shahbazian A, Ji S, Boström KI. Highdensity lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2. Arterioscler Thromb Vasc Biol. 2008;28:2266-2274.
40. Lomashvili KA, Wang X, Wallin R, O'Neill WC. Matrix GLA protein metabolism in vascular smooth muscle and role in uremic vascular calcification. J Biol Chem. 2011;286:28715-28722.
41. Napoli C, Quehenberger O, De Nigris F, Abete P, Glass CK, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 2000;14:1996-2007.
42. Hulsmans M, Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med. 2010;14:70-78.
43. Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant. 2009; 24:2051-2058.
44. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, Frutkin A, Dichek D, Giachelli CM. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104:733-741.
45. Yu PB, Deng DY, Beppu H, Hong CC, Lai C, Hoyng SA, Kawai N, Bloch KD. Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem. 2008;283:3877-3888.
46. Sorescu GP, Sykes M, Weiss D, Platt MO, Saha A, Hwang J, Boyd N, Boo YC, Vega JD, Taylor WR, Jo H. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem. 2003;278:31128-31135. (Pubitemid 36994628)
47. Wong WT, Tian XY, Chen Y, Leung FP, Liu L, Lee HK, Ng CF, Xu A, Yao X, Vanhoutte PM, Tipoe GL, Huang Y. Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase-2 upregulation: implications on hypertension. Circ Res. 2010; 107:984-991.
48. Wang L, Harrington L, Trebicka E, Shi HN, Kagan JC, Hong CC, Lin HY, Babitt JL, Cherayil BJ. Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest. 2009;119:3322-3328.
49. Lee GT, Kwon SJ, Lee JH, Jeon SS, Jang KT, Choi HY, Lee HM, Kim WJ, Kim SJ, Kim IY. Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways. J Biol Chem. 2010;285:39401-39408.
50. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, Kamiya N, Fukuda T, Mishina Y, Peterson RT, Bloch KD. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med. 2008;14:1363-1369.
51. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010;53:713-718.
52. Tsuji K, Cox K, Bandyopadhyay A, Harfe BD, Tabin CJ, Rosen V. BMP4 is dispensable for skeletogenesis and fracture-healing in the limb. J Bone Joint Surg Am. 2008;90 (Suppl 1):14-18. (Pubitemid 351329115)
53. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, Einhorn T, Tabin CJ, Rosen V. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet. 2006;38:1424-1429. (Pubitemid 44837565)